PHT Corporation Delivers Unique Rater Training Programs to Improve Instrument Reliability, Data Quality and Outcomes
Improves data quality and regulatory compliance by combining scientific training with innovative electronic implementation of instruments
BOSTON, Mass. and GENEVA, Switzerland – The pharmaceutical industry is further optimizing the collection of high quality electronic patient reported outcomes (ePROs) data for clinical research, with PHT CorporationRater Training programs. PHT is the leading provider of patient-driven eData systems used to collect outcomes for better clinical research. Three distinct rater training programs developed by the PHT Clinical Science and Consulting team of world-class scientists are now available. The PHT Rater Training courses are based on industry’s need to standardize data collection among clinicians, observers and patients.
Join PHT scientists at a new live webinar February 11 “Make Every Data Point Count: The Importance of Rater Training in Clinical Trials.” Register today: http://bit.ly/14WWnBt
Rater Training for clinician reported outcome (ClinRO), observer reported outcome (ObsRO) and patient reported outcome (PRO) assessments ensures and improves data accuracy by reducing leniency, severity, halo, first impression, and friendship bias. Recommended by global regulators and endorsed by ISPOR, rater training clarifies each instrument’s performance dimensions used in the evaluation system, and advances the detection, perception, and recall of actual performance.
PHT Vice President of Clinical Science and Consulting Dr. Susan M. Dallabrida – one of the 2014 PharmaVOICE 100 most inspiring people in life sciences – explained, “Studies show that clinical experience does not substitute for clinician rater training, which is proven to reduce inter-rater variability and instrument scoring deviations. Rater training for clinicians, caregivers and patients enables standard and uniform use of scales across the trial population and improves data quality leading to an increased signal to noise ratio.” Hear more from Dr. Dallabrida on the value of Rater Training: bit.ly/1zfFXOu
PHT Rater Training programs train clinicians, caregivers and patients on trial instruments and their electronic implementations for optimal data quality. Sponsors are increasingly choosing PHT to provide Rater Training on clinical measures such as:
- Columbia-Suicide Severity Rating Scale (C-SSRS) Screening/Baseline (SB) and Since Last Visit (SLV) Adult and Pediatric versions
- Sheehan Suicidality Tracking Scale (Sheehan-STS)
Only PHT provides a customized IM Science Rater Training Workshop to ensure all clinical trial participants are fully versed on the significance of rater scoring. The Workshop is presented by a PHT Clinical Scientist and includes interactive training and quiz sessions. PHT Rater Training programs are helping trial sponsors increase the value and ROI of their eCOA Systems through improved data quality.
About PHT Corporation
PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for better clinical research. Visit phtcorp.com for more information on PHT. Follow PHT on LinkedIn, Facebook, Twitter, Google+ and YouTube.
Media contact: Brenda Nashawaty, brenda@nashawaty.com, 617-688-3253
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
